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Doxycycline versus prednisolone as an initial treatment 
strategy for bullous pemphigoid: a pragmatic, 
non-inferiority, randomised controlled trial
Hywel C Williams, Fenella Wojnarowska, Gudula Kirtschig, James Mason, Thomas R Godec, Enno Schmidt, Joanne R Chalmers, Margaret Childs, 
Shernaz Walton, Karen Harman, Anna Chapman, Diane Whitham, Andrew J Nunn, on behalf of the UK Dermatology Clinical Trials Network 
BLISTER Study Group*
Summary
Background Bullous pemphigoid is a blistering skin disorder with increased mortality. We tested whether a strategy of 
starting treatment with doxycycline gives acceptable short-term blister control while conferring long-term safety 
advantages over starting treatment with oral corticosteroids.
Methods We did a pragmatic, multicentre, parallel-group randomised controlled trial of adults with bullous 
pemphigoid (three or more blisters at two or more sites and linear basement membrane IgG or C3). Participants were 
randomly assigned to doxycycline (200 mg per day) or prednisolone (0·5 mg/kg per day) using random permuted 
blocks of randomly varying size, and stratified by baseline severity (3–9, 10–30, and >30 blisters for mild, moderate, 
and severe disease, respectively). Localised adjuvant potent topical corticosteroids (<30 g per week) were permitted 
during weeks 1–3. The non-inferiority primary effectiveness outcome was the proportion of participants with three or 
fewer blisters at 6 weeks. We assumed that doxycycline would be 25% less effective than corticosteroids with a 
37% acceptable margin of non-inferiority. The primary safety outcome was the proportion with severe, life-threatening, 
or fatal (grade 3–5) treatment-related adverse events by 52 weeks. Analysis (modified intention to treat [mITT] for the 
superiority safety analysis and mITT and per protocol for non-inferiority effectiveness analysis) used a regression 
model adjusting for baseline disease severity, age, and Karnofsky score, with missing data imputed. The trial is 
registered at ISRCTN, number ISRCTN13704604.
Findings Between March 1, 2009, and Oct 31, 2013, 132 patients were randomly assigned to doxycycline and 121 to 
prednisolone from 54 UK and seven German dermatology centres. Mean age was 77·7 years (SD 9·7) and 173 (68%) 
of 253 patients had moderate-to-severe baseline disease. For those starting doxycycline, 83 (74%) of 112 patients had 
three or fewer blisters at 6 weeks compared with 92 (91%) of 101 patients on prednisolone, an adjusted difference of 
18·6% (90% CI 11·1–26·1) favouring prednisolone (upper limit of 90% CI, 26·1%, within the predefined 37% margin). 
Related severe, life-threatening, and fatal events at 52 weeks were 18% (22 of 121) for those starting doxycycline and 
36% (41 of 113) for prednisolone (mITT), an adjusted difference of 19·0% (95% CI 7·9–30·1), p=0·001.
Interpretation Starting patients on doxycycline is non-inferior to standard treatment with oral prednisolone for 
short-term blister control in bullous pemphigoid and significantly safer in the long-term.
Funding NIHR Health Technology Assessment Programme.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license.
Introduction
Bullous cutaneous pemphigoid is the most common 
autoimmune blistering skin disease characterised by 
autoantibodies against structural skin proteins of the 
dermal–epidermal junction.1 Annual incidence of bullous 
pemphigoid in the UK and central Europe ranges between 
14 and 42 new patients per million inhabitants and has 
doubled within the last decade.2,3 Bullous pemphigoid is 
an intensely itchy condition characterised by erythema 
studded with tense blisters, some of which might become 
infected. The disorder is commoner in those older than 
70 years and runs a chronic progressive course.4 It is 
associated with increased morbidity and mortality,2,5 
neurological diseases including dementia,6,7 Parkinson’s 
disease, motor neurone disease and stroke,6–8 
haematological malignancies,9 and exposure to some 
medications,8 such as loop diuretics.10 Oral prednisolone 
has been the standard treatment for bullous pemphigoid 
for more than 50 years,4,11 but is associated with clinically 
significant adverse effects in the elderly and the optimal 
dose is uncertain. Prolonged whole body application of 
super-potent topical corticosteroids has been shown to be 
effective in bullous pemphigoid,12 with less morbidity and 
mortality than oral high-dose corticosteroid treatment.3,13 
However, this regimen might not be practical for patients 
with limited mobility and limited help from carers to 
apply whole body ointments daily. Systemic absorption 
when applied to the whole body might be considerable,12 
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so there remains a need for an oral treatment that is safe 
and effective. Tetracyclines have been used in bullous 
pemphigoid for their anti-inflammatory action,14,15 but a 
Cochrane systematic review found only one small study 
supporting their use.16 It is unlikely that tetracyclines 
would be more effective than oral prednisolone, but they 
are expected to be safer in the long term. We did a survey 
of UK dermatologists that suggested most were willing to 
accept a 25% reduction in early blister control with 
doxycycline provided there was at least a 20% reduction in 
serious related side-effects compared with prednisolone. 
The Bullous Pemphigoid Steroids and Tetracyclines 
(BLISTER) study17 tested whether a strategy of starting 
treatment with tetracyclines produces an acceptable 
degree of short-term blister control compared with oral 
corticosteroids (a non-inferiority comparison), while 
conferring a long-term safety advantage over oral 
corticosteroids (a superiority comparison) in a pragmatic 
way that could inform everyday clinical practice.
Methods
Study design and participants
The study was a two-group parallel pragmatic multicentre 
randomised controlled clinical trial of 52 weeks duration 
done in dermatology specialist clinics in the UK and 
Germany.18,19 The trial used a non-inferiority approach to 
compare short-term effectiveness and a superiority 
approach to compare long-term safety.17,18
Adults (≥18 years of age) attending dermatology specialist 
clinics with suspected bullous pemphigoid and at least 
three clinically significant blisters appearing on at least two 
body sites within the last week and who were able to 
provide written informed consent were enrolled. Clinically 
significant blisters were defined as cutaneous blisters at 
least 5 mm in diameter, inclusive of ruptured blisters with 
a flexible (not dry) roof covering a moist base. All patients 
with suspected bullous pemphigoid had their clinical 
diagnosis confirmed by positive direct or indirect 
immunofluorescence (IgG or C3 at the dermal–epidermal 
junction or both) or were subsequently excluded if 
immunofluorescence was negative. Further exclusions 
were a diagnosis of mucous membrane pemphigoid; a 
documented diagnosis of active bullous cutaneous 
pemphigoid in the year before randomisation; use of study 
medications in the previous 12 weeks; recent (3 months or 
less) administration of a live virus vaccine; known allergy 
to any member of the tetracycline family; presence of any 
condition or use of any medication which precludes the 
use of either of the study drugs; women of childbearing 
potential who are not taking adequate contraception or 
who are pregnant, plan to become pregnant during the 
study duration or lactating; any other condition which 
would, in the investigator’s opinion, deem the patient 
unsuitable for participation in the study (eg, condition 
requiring long-term or frequent oral steroid use); and 
patient participating in any other intervention study.
Trial oversight was by a Trial Steering Committee and 
an independent Data Monitoring Committee. Ethics 
permission was granted for the UK by Central 
Manchester Research Ethics Committee (Nov 12, 2008; 
reference 08/H1008/174) and for Germany by Ethik-
Kommission der Universität zu Lübeck, Medizinische 
Fakultät (Aktenzeichen 09-134). The trial protocol and 
statistical analysis plan are available online.
Research in context
Evidence before this study
We updated a Cochrane systematic review of interventions for 
bullous pemphigoid in 2010 (no language restrictions) and found 
ten randomised controlled studies, only one of which 
(20 participants) tested use of tetracyclines—despite their 
widespread use. We searched the Cochrane Library and PubMed 
for publications from Aug 1, 2010, to Nov 1, 2016, using the term 
“pemphigoid” and did not find any new trials of tetracyclines for 
bullous pemphigoid. The most substantial advance in pemphigoid 
treatment in the last 10 years has been the demonstration of good 
response rates for superpotent and potent topical corticosteroids 
applied to the whole body for prolonged periods with substantial 
reduction in mortality when compared with oral prednisolone. 
Use of topical steroid treatment is partly limited by side-effects 
such as skin thinning and practical considerations such as reduced 
mobility or lack of carer support to enable elderly patients to apply 
whole body ointments daily, so there is still a need for an oral 
treatment for bullous pemphigoid that is safer than prednisolone.
Added value of this study
Our study provides new information that supports our 
hypothesis that starting patients with bullous pemphigoid on 
oral doxycycline 200 mg per day produces acceptable blister 
control in the short term (within our a-priori non-inferiority 
limits), with better long-term safety than starting on 
prednisolone 0·5 mg/kg per day. We did not find any evidence 
that the treatment response differed between the 
two strategies according to the severity of blisters at baseline. 
The relative trade-off of blister control versus long-term 
safety provides key information for shared decision making 
between patients with bullous pemphigoid and doctors.
Interpretation of all the available evidence
Topical corticosteroid treatment still probably offers the best 
trade-off between blister control and long-term safety when 
compared with oral prednisolone, but prolonged whole body 
topical treatment might not always be practical in some 
patients, such as the elderly. In individuals with bullous 
pemphigoid who need oral therapy, our study suggests that 
initiating treatment with doxycycline might produce 
acceptable blister control and better long-term safety than 
standard treatment with oral prednisolone.
For more on the trial protocol 
and statistics analysis plan see 
http://www.nottingham.ac.uk/
research/groups/cebd/
projects/5rareandother/index.
aspx
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Randomisation and masking
Participants were randomly assigned (1:1) to receive either 
doxycycline or prednisolone as initial treatment, and 
followed up for skin and medication assessments at 
weeks 3, 6, 13, 26, 39, and 52, plus unscheduled visits as 
required, reflecting normal clinical care. Randomisation 
was done by the internet and occurred once recruited 
participants’ details had been entered by local physicians 
and research nurses onto a study database. Treatment was 
allocated using random permuted blocks of randomly 
varying size generated by the Nottingham Clinical Trials 
Unit and was stratified by baseline severity (3–9, 10–30, 
and >30 blisters for mild, moderate, and severe disease, 
respectively). Treatment allocation was sent directly to the 
local pharmacist who dispensed the appropriate 
medication directly, allowing the investigator to remain 
masked for the first 6 weeks. Investigators were 
subsequently unmasked to adjust or switch medication 
to reflect normal clinical practice. Participants were 
not masked to study medications. Given the morbidity 
of the elderly population and the fact that the 
characteristic adverse events of each drug are very well 
described, only adverse events suspected to be related were 
recorded. Adverse event collection after 6 weeks was not 
masked. Relatedness of unclear serious adverse events and 
all deaths was judged by a senior dermatologist 
independent of the trial team.
Procedures
We compared a strategy of initial treatment with oral 
doxycycline 200 mg per day or oral prednisolone 
0·5 mg/kg per day for 6 weeks until the primary 
effectiveness outcome was measured, followed by a 
period in which the investigators were unmasked to 
treatments so that they could either continue with the 
randomised treatment if blister control was adequate, or 
switch treatments or adjust the dose of prednisolone, as 
might occur in normal clinical practice. Treatment with 
either strategy could continue up to 12 months according 
to blister control and adverse effects. We chose doxycycline 
because oxytetracycline requires participants to swallow 
eight large tablets daily and doxycycline has fewer adverse 
effects.20 We chose a dose of 0·5 mg/kg per day of 
prednisolone because a previous systematic review 
suggested higher doses were associated with unacceptable 
serious adverse effects16 and lower doses might be 
ineffective.21 Up to 30 g per week of a potent topical 
corticosteroid (mometasone furoate) was permitted to be 
applied to localised lesions for symptom relief for 
weeks 1–3 only, and again after 6 weeks as per normal 
practice.15 Only lesional and not whole body application of 
topical corticosteroids was permitted.
Outcomes
We included two primary outcomes to measure the trade-
off between effectiveness (initial blister control) and 
safety (serious adverse effects) for the two treatment 
strategies. Short-term control (effectiveness) was 
measured at 6 weeks after randomisation, and long-term 
safety was measured at 52 weeks after randomisation. 
The primary outcomes were the absolute difference 
between the treatment groups in: the proportion of 
participants classed as treatment success (three or fewer 
significant blisters) at 6 weeks, regardless of whether 
their treatment had been modified because of a poor 
response (non-inferiority effectiveness comparison of 
treatment strategy); and the proportion of participants 
with grade 3–5 (severe, life-threatening, or fatal) adverse 
events that were possibly, probably, or definitely related 
to the treatment in the 52 weeks following randomisation 
(superiority safety comparison). A modified version of 
the Common Terminology Criteria for Adverse Events 
(version 3.0) was used.
Secondary effectiveness outcomes were the proportion 
of participants who were deemed treatment successes 
(three or fewer significant blisters and no treatment 
modification before 6 weeks as a more direct comparison 
of drug rather than treatment strategy), the proportion 
classed as treatment success at 13 and 52 weeks (three or 
fewer significant blisters and no treatment modification), 
and relapses (those with further episodes of bullous 
pemphigoid during the study who had previously been 
classed as success). Secondary safety outcomes were the 
proportion reporting related adverse events of any grade 
up to week 52, participants classed as a treatment 
success at 6 weeks still alive at 52 weeks, quality of life 
(EuroQoL EQ-5D-3L and Dermatology Life Quality 
Index [DLQI] questionnaires at 6, 13, 26, 39, and 
52 weeks), and cost-effectiveness over 12 months from a 
UK health service perspective. The cost-effectiveness 
analysis will be published in detail elsewhere.
Tertiary outcomes were the proportion of participants 
who were deemed treatment successes (three or fewer 
significant blisters and no treatment modification) at 
3 weeks, proportion of patients completely blister free by 
6 weeks, all-cause mortality at 52 weeks, and the amount 
of localised use of potent and super-potent topical 
corticosteroids (as recorded in the treatment log by local 
physicians).
Statistical analysis
For the safety primary endpoint, 256 patients were 
needed to show a reduction from 60% to 40% in adverse 
reactions of grade 3 or more for those started on doxy-
cycline compared with prednisolone, with 80% power, 
5% significance, and allowing for 20% loss to follow-up 
at 1 year.13,22 When estimating the number of participants 
required for the effectiveness analysis we assumed that 
doxycycline would be less effective than prednisolone, 
with around 70% having three or fewer blisters at 6 weeks 
compared with 95% in the prednisolone-initiated group, 
an absolute difference of 25%, based on published data 
and expert opinion. We set the acceptable non-inferiority 
margin at 37%, corresponding to the upper bound of the 
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90% CI for the anticipated 25% difference in 
effectiveness. This required a total of 234 participants to 
show non-inferiority with 80% power, allowing for a 
5% expected dropout by 6 weeks. For initial treatment 
with doxycycline to be considered an acceptable 
alternative strategy to prednisolone, both superiority for 
safety and non-inferiority for effectiveness had to be 
shown. Because bullous pemphigoid is rare and mainly 
seen in the very elderly, we were restricted in the number 
of participants we could realistically expect to recruit. The 
smaller the non-inferiority margin, the greater the 
sample size, so to set the margin closer to the expected 
25% difference in effectiveness would have required an 
unrealistically large sample size. Therefore, the non-
inferiority margin was set at 37% (the 25% expected 
difference plus a further 12%) which meant that 
234 participants would be sufficient. Thus 37% was the 
maximum allowable difference for a strategy of starting 
treatment with doxycycline to be considered non-inferior. 
Given these considerations and the sample size required 
for the safety analysis it was decided to recruit a total of 
256 patients. For initial treatment with doxycycline to 
be considered an acceptable alternative strategy to 
prednisolone, non-inferiority had to be shown for 
effectiveness and superiority for safety.
Analysis used a binomial regression model with an 
identity link function adjusting for baseline severity of 
bullous pemphigoid, patient age, and Karnofsky score for 
functional impairment to estimate the absolute difference 
between the two treatment groups, and missing data were 
imputed. Superiority analyses were done on a modified 
intention-to-treat basis (participants who fulfilled eligibility 
were randomly assigned to either of the study drugs and 
had data on the outcome of interest as pre-defined in our 
protocol) and non-inferiority analyses were done on both 
modified intention-to-treat and per-protocol populations 
according to recommended practice23 and according to the 
protocol and statistical analysis plan. The per-protocol 
population for the non-inferiority outcomes at weeks 3 and 
6 was defined as those participants who for reasons other 
than treatment success or failure (determined by the 
investigators) had not increased their dose of allocated 
treatment, changed treatment or added a new treatment to 
their allocated treatment, used topical steroids between 
visit weeks 3 and 6 (week 6 outcome only), missed more 
than 3 consecutive treatment days, or committed other 
deviations deemed to be violations by an independent 
adjudicator masked to treatment allocation. After week 6, 
the per-protocol population for non-inferiority analyses 
was those included in 6-week primary effectiveness per-
protocol analysis who had not missed more than 
3 consecutive weeks of allocated treatment between 
6 weeks and 52 weeks (regardless of whether their dose 
had been increased or decreased) unless they had stopped 
for good clinical response, those who had not used more 
than 30 g of potent topical steroids per week after week 6, 
had not added systemic steroids to doxycycline (if allocated) 
or doxycycline or another immunosuppressant to 
prednisolone (if allocated) unless for poor clinical 
response, or did not commit other protocol deviations 
deemed as violations by an independent adjudicator.
Multiple imputation methods for dealing with missing 
data for the primary safety analyses can be found in the 
statistical analysis plan. Two planned subgroup analyses 
for treatment success at 6 weeks explored interactions 
with baseline disease severity and instances where 
investigators had become unmasked to treatment 
allocation before week 6.
Figure 1: Trial profile for the primary outcome population
Those patients excluded from analysis at week 6 due to missing their week 6 assessment are included in the 
denominator at week 52, as they had the possibility of attending a visit after week 6 and therefore were not 
considered lost to follow-up at week 6. Patients who did not attend their week 52 visit are called lost to follow-up 
at week 52. The primary safety analysis (mITT) was based on 121 and 113 participants allocated to initial 
doxycycline and prednisolone, respectively, who had at least one return visit. Multiple imputation was used for 
missed visits as specified in the protocol. mITT=modified intention to treat.
1604 assessed for eligibility
1326 ineligible
157 <3 blisters or <2 body parts
75 controlled by topical therapy
486 already received trial medications
145 substantial comorbidities
98 refused consent
162 unable to consent
166 other reasons
37 no reason given 
278 randomly assigned
138 allocated to prednisolone
17 excluded
15 immunofluorescence test negative
1 insufficient number of blisters
1 already taking prednisolone
121 patients in the prednisolone group
20 not assessed at 6 weeks
10 withdrew
5 died before visit
5 missed 6 week appointment
101 in the primary effectiveness analysis 
at 6 weeks (mITT)
23 post 6 weeks not available for 52 weeks 
assessment 
13 withdrew
9 died before visit
1 lost to follow-up
78 attended the week 52 visit
113 included in primary safety
        analysis at 52 weeks (mITT)
140 allocated to doxycycline
8 excluded
4 immunofluorescence test negative
1 uncertain diagnosis or need of treatment
1 used prednisolone within last 12 weeks
1 diagnosis of nodular prurigo
1 study centre too far to travel
132 patients in the doxycycline group 
20 not assessed at 6 weeks
16 withdrew
2 died before visit
2 missed 6 week appointment
112 in the primary effectiveness analysis 
at 6 weeks (mITT)
34 post 6 weeks not available for 52 weeks
assessment  
20 withdrew
10 died before visit
4 lost to follow-up
78 attended the week 52 visit 
121 included in primary safety
  analysis at 52 weeks (mITT)
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There were no substantial changes to the main study 
protocol after recruitment started. The trial is registered 
at ISRCTN, number ISRCTN13704604.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, writing of 
the report, or decision to submit the results for 
publication. The corresponding author and trial 
statisticians had full access to all the data in the study. All 
authors in the writing team shared final responsibility 
for the decision to submit for publication. The full report 
submitted to the funder is available elsewhere.17
Results
We randomly allocated 278 participants from dermatology 
specialist clinics in 54 UK and seven German 
centres. Recruitment commenced on March 1, 2009, in 
the UK and Feb 1, 2010, in Germany, and ended on 
Oct 31, 2013. 19 participants were excluded because their 
immunofluorescence tests were negative and six for 
other reasons; 253 participants (132 in the doxycycline 
group and 121 in the prednisolone group) were available 
for analysis (figure 1). Baseline characteristics of the 
study population in both treatment groups were similar 
(table 1). Average age was 77·7 years (SD 9·7); 
80 (32%) participants had mild disease, 99 (39%) had 
moderate disease, and 74 (29%) had severe disease. The 
number and primary reasons for withdrawal from the 
trial are in the appendix.
For the primary outcome, the number of participants 
who achieved success (three or fewer significant blisters) 
with doxycycline-initiated treatment was 83 (74%) of 
112 patients compared with 92 (91%) of 101 patients 
started on prednisolone, an adjusted difference of 18·6% 
(90% CI 11·1–26·1; table 2). The upper bound CI of 
26·1% for the adjusted difference fell within the 37% pre-
specified acceptable margin for the 90% CI. This value 
remained close regardless of whether a modified 
intention-to-treat or per-protocol analysis was used or 
whether adjusted by severity and Karnofsky score as 
shown in figure 2.
Subgroup analysis of the primary outcome according 
to baseline severity shows that the benefit of both 
treatments diminishes in severe disease, although there 
was no significant interaction between treatment effect 
and severity (pinteraction=0·874 for moderate vs mild baseline 
severity and pinteraction=0·431 for severe vs mild baseline 
severity; table 2). Subgroup analysis of the primary 
outcome according to whether masking was 
compromised did not show any evidence of interaction 
for modified intention-to-treat (p=0·333) or per-protocol 
analyses (p=0·356).
For the primary safety outcome, the number of patients 
experiencing a treatment-related severe, life-threatening, 
or fatal adverse event by 52 weeks was 22 (18%) of 121 for 
patients started on doxycycline compared with 41 (36%) 
of 113 for those starting on prednisolone, a difference of 
18·1% (95% CI 6·9–29·3, p=0·002) when unadjusted, 
and 19·0% (7·9–30·1, p=0·001) after adjusting for 
baseline disease severity (table 3). Similar results were 
seen with imputed missing values (table 3). There were 
three treatment-related deaths in the doxycycline-
initiated group compared with 11 in the prednisolone-
initiated group. The total number of related adverse 
events and maximum grade of related adverse events 
(≥grade 3) are shown in the appendix (pp 2, 3).
The proportion of patients achieving treatment success 
defined as three or fewer significant blisters and no 
treatment modification before 6 weeks in the modified 
intention-to-treat population was 60 (54%) of 112 in 
the doxycycline group and 88 (85%) of 103 in the 
prednisolone group (difference in favour of prednisolone 
31·8% [90% CI 22·5–41·2] after adjusting for baseline 
disease severity and age). The proportion achieving 
Doxycycline 
(n=132)
Prednisolone 
(n=121)
Total 
(n=253)
Sex
Female 63 (48%) 57 (47%) 120 (47%)
Male 69 (52%) 64 (53%) 133 (53%)
Age (years) 78·1 (9·5) 77·2 (10·0) 77·7 (9·7)
<65 8 (6%) 14 (12%) 22 (9%)
65–74 38 (29%) 33 (27%) 71 (28%)
75–84 51 (39%) 45 (37%) 96 (38%)
≥85 35 (27%) 29 (24%) 64 (25%)
Karnofsky score 69·0 (18·3) 70·5 (18·6) 69·7 (18·0)
<40 3 (2%) 1 (1%) 4 (2%)
40–54 32 (24%) 26 (21%) 58 (23%)
55–69 21 (16%) 24 (20%) 45 (18%)
70–84 45 (34%) 38 (31%) 83 (33%)
≥85 31 (23%) 32 (26%) 63 (25%)
Unable to care for self 16 (12%) 11 (9%) 27 (11%)
Unable to work 55 (42%) 51 (42%) 106 (42%)
Able* 61 (46%) 59 (49%) 120 (47%)
Ethnicity
White 112 (85%) 100 (83%) 212 (84%)
Black African 1 (1%) 1 (1%) 2 (1%)
Black other 0 1 (1%) 1 (<1%)
Asian Indian 2 (2%) 1 (1%) 3 (1%)
Asian Chinese 1 (1%) 0 1 (<1%)
Asian other 2 (1·5%) 1 (1%) 3 (1%)
Other 0 1 (1%) 1 (<1%)
Not known or not given 14 (11%) 16 (13%) 30 (12%)
Severity of bullous pemphigoid
Mild (3–9 blisters) 42 (32%) 38 (31%) 80 (32%)
Moderate 
(10–30 blisters)
53 (40%) 46 (38%) 99 (39%)
Severe (>30 blisters) 37 (28%) 37 (31%) 74 (29%)
Data are n (%) or mean (SD). *Able to carry on normal activity and to work; 
no additional care needed.
Table 1: Baseline characteristics of trial participants
See Online for appendix
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treatment success without treatment modification 
(modified intention-to-treat population) at 3 weeks was 
67 (56%) of 119 patients in the doxycycline group compared 
with 90 (81%) of 111 patients in the prednisolone group 
(difference 23·4% [90% CI 14·4–32·5] after adjusting for 
Karnofsky score). At 13 weeks, the numbers were 58 (59%) 
of 99 patients in the doxycycline group and 76 (75%) of 
101 patients in the prednisolone group (adjusted difference 
17·5% [90% CI 6·8–28·2]), and at 52 weeks, 34 (41%) of 
83 patients in the doxycycline group and 45 (51%) of 
88 patients in the prednisolone group (adjusted difference 
10·0% [90% CI –2·3 to 22·2]).
Relapse rates (more than three blisters for those 
initially classed as treatment success at 6 weeks) were 
similar in both groups: 37 (32%) of 114 patients in the 
doxycycline group and 39 (36%) of 109 patients in the 
prednisolone group, an adjusted difference of 2·1% 
(90% CI –8·3 to 12·5; appendix p 4).
Patients in the prednisolone group were more likely to 
be completely blister free at 6 weeks than those in the 
doxycycline group (74 [73%] of 101 patients vs 51 [46%] of 
111 patients, an adjusted difference of 28·6% (90% CI 
18·1–39·1). Topical corticosteroid use for symptomatic 
relief was greater for those initiated on doxycycline 
treatment (appendix p 4).
Patients in the prednisolone group were significantly 
more likely to experience treatment-related adverse 
events of any grade during the study than those in the 
doxycycline group (96% vs 86%, difference 9·5% [95% CI 
1·8–17·2], p=0·016, unadjusted because of non-
convergence in the model).
The total number of related adverse events (all grades) 
and maximum grade are shown in the appendix (p 5). 
Safety analysis of all-cause mortality showed that patients 
started on prednisolone were more likely to die during 
the year than those who started on doxycycline (101 [83%] 
of 121 patients vs 118 [89%] of 132 patients alive at 1 year; 
appendix pp 6, 7). The Kaplan Meier survival plot of time 
to death is in the appendix (p 8).
The combined superiority analysis of effectiveness 
and safety (treatment success at 6 weeks and alive at 
52 weeks) showed a difference of 25·0% (95% CI 
13·1–37·0) in favour of prednisolone after adjusting for 
baseline disease severity and age (77 [75%] of 103 patients 
in the prednisolone group vs 56 [50%] of 112 patients in 
the doxycycline group).
For quality of life assessed by EQ-5D the difference in 
score was not significant when adjusted for baseline 
score, baseline disease severity, age, or Karnofsky score 
(adjusted difference 0·045 [95% CI –0·015 to 0·106], 
p=0·143; appendix p 9).
Both groups experienced similar improvement in 
DLQI scores with median improvement of 9 and 
10 points from baseline in the doxycycline and 
prednisolone groups, respectively. When adjusted for 
baseline DLQI, disease severity, age, and Karnofsky 
score, there was a small but significant difference of –1·8 
(95% CI –2·58 to –1·01, p<0·0001) in favour of 
doxycycline (appendix p 10).
Figure 2: Proportion of participants who achieved treatment success at 
6 weeks: the modified intention-to-treat and per-protocol analyses
0 5 10 15 20 25 30 35 40
Per protocol
Modified 
intention to treat
Difference in percentage successfully treated at
week 6 (prednisolone–doxycycline)
37% margin of
non-inferiority18·6
(90% CI 11·1–26·1)
18·7
(90% CI 9·8–27·6)
mITT population* 
(all severities†)
Per-protocol 
population‡
mITT population*
Mild disease† Moderate disease† Severe disease†
Prednisolone (n/N, %) 92/101 (91%) 84/91 (92%) 30/31 (97%) 41/42 (98%) 21/28 (75%)
Doxycycline (n/N, %) 83/112 (74%) 58/78 (74%) 28/37 (76%) 36/46 (78%) 19/29 (66%)
Adjusted difference in 
proportions (%, 90% CI)
18·6% (11·1 to 26·1)§ 18·7% (9·8 to 27·6)§ 21·1% (7·7 to 34·5)¶ 19·3% (7·7 to 31·0)¶ 9·5% (–10·4 to 29·4)¶
Unadjusted difference in 
proportions (%, 90% CI)
17·0% (8·7 to 25·2) 17·9% (8·6 to 27·3) 21·1% (8·4 to 33·8) 19·4% (8·6 to 30·1) 9·5% (–10·3 to 29·3)
pinteraction|| ·· ·· ·· 0·874 0·431
For doxycycline to be considered non-inferior to the control treatment, the upper bound of the 90% CI should fall below 37%. mITT=modified intention to treat. *All randomised 
patients who had a blister count at 6 weeks. †Baseline severity; mild=<10 blisters at baseline; moderate=10–30 blisters at baseline; severe=>30 blisters at baseline. ‡Those 
participants who before their 6 week visit had not increased the dose of their allocated treatment, changed treatment, or added a new treatment to their allocated treatment 
(for a reason other than for treatment failure or success), used topical steroids between visit weeks 3 and 6, or missed more than 3 consecutive days of treatment. §Estimates are 
from a regression model adjusted for baseline severity of bullous pemphigoid and Karnofsky score; age was omitted from the model due to model non-convergence when 
present. ¶Estimates are from a regression model containing an interaction between treatment group and baseline severity of disease, also adjusted for Karnofsky score; age was 
omitted from the model due to model non-convergence when present. ||A post-hoc test for interaction was done comparing the mild disease group with both the moderate and 
the severe disease groups for the adjusted model; a global interaction test gave a pinteraction of 0·709.
Table 2: Proportion of participants who achieved treatment success (three or fewer blisters) at 6 weeks by modified intention-to-treat and per-protocol 
analyses, and subgroup analysis of baseline disease severity and treatment effect by modified intention-to-treat analysis
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Because three or more significant blisters was an 
inclusion criterion and treatment success was defined as 
three or fewer blisters, it is possible that some participants 
in the mild group could have experienced little or no 
change in blister status. No worsening in these patients 
at 6 weeks is a good result. However, when those in the 
mild severity group who had one to three blisters at 
6 weeks (14 in the doxycycline group and seven in the 
prednisolone group) were re-categorised as no change in a 
post-hoc sensitivity analysis, there was no change in the 
magnitude or direction of the primary effectiveness 
outcome (85 [90%] of 94 patients had treatment success on 
prednisolone and 69 [70%] of 98 patients on doxycycline, a 
difference of 20·0% [90% CI 10·9–29·1%], in an adjusted 
modified intention-to-treat analysis analysis).
Discussion
We have shown that a strategy of starting treatment for 
bullous pemphigoid with doxycycline 200 mg daily 
produces acceptable short-term effectiveness that resides 
within our predefined non-inferiority margin, and 
significant safety gains at 1 year compared with initiating 
treatment with prednisolone 0·5 mg/kg per day. 
Although we did not find clear evidence that differences 
between the two treatment strategies varied by baseline 
disease severity, our study suggests that effectiveness of 
either strategy is modest for those with severe disease.
Although previous studies3,13 have shown good blister 
control and better safety for prolonged use of super-
potent topical corticosteroids over the whole body when 
compared with high-dose oral prednisolone (mg/kg per 
day), such a regimen might be impractical for some 
patients and carers.24 Prolonged topical corticosteroid use 
also causes adverse effects such as skin thinning, and 
those effects associated with systemic absorption.3,13 Most 
guidelines still recommend oral prednisolone (between 
0·5 mg/kg per day and 1·5 mg/kg per day according 
to initial severity).12,25 Most guidelines mention the 
widespread use of tetracyclines in bullous pemphigoid, 
but cite the lack of high-quality evidence to inform this 
treatment recommendation. The Cochrane review16 of 
bullous pemphigoid found only one randomised study of 
18 patients treated with tetracycline and nicotinamide 
versus prednisolone, which had inconclusive results;26 
none have been published since. The BLISTER study fills 
this gap.
Study strengths include the relatively large sample size 
and pragmatic design that permitted dose adjustment, 
switching, and additional treatments as per normal 
clinical practice. The perspective of the trial was one of a 
long-term treatment strategy of starting patients with 
bullous pemphigoid on doxycycline versus prednisolone 
rather than a direct efficacy study comparing sole use of 
each drug. If we had used our secondary outcome 
(proportion achieving treatment success at 6 weeks 
defined as three or fewer significant blisters but no 
treatment modification before 6 weeks), then the 
doxycycline group would have narrowly failed to achieve 
non-inferiority according to our predefined margins.
It is unlikely that the localised use of small quantities 
of topical corticosteroids for symptomatic relief permitted 
in the first 3 weeks of treatment affected effectiveness 
comparisons at 6 weeks. The nature of such localised 
topical treatment for symptom relief is very different 
from the whole-body application of large quantities of 
super-potent or potent topical corticosteroids used in 
other studies.3,13 Per-protocol analyses that excluded 
participants who used topical corticosteroids in weeks 4–6 
showed very similar results to the modified intention-to-
treat analysis in which they were included.
Participants were representative of those presenting to 
secondary care from multiple centres in the UK and 
Germany. Indirect immunofluorescence on human split-
skin was not done at all centres, so it is possible that a 
small number of participants with epidermolysis bullosa 
acquisita were included. However, epidermolysis bullosa 
acquisita accounts for less than 5% of pemphigoid 
disorders, is often unreactive by indirect immuno-
fluorescence microscopy on monkey oesophagus, and 
any cases would have been randomly distributed between 
the treatment groups. Furthermore, none of the study 
centres reported that the diagnosis of pemphigoid was 
revised to another disease during the 1 year of follow-up. 
It is also worth emphasising that any potential 
participants who did not show a clear direct or indirect 
positive immunofluorescence were excluded from the 
study and were replaced by other participants with clear 
evidence of bullous pemphigoid. Masking of outcome 
assessment in the first 6 weeks was largely maintained. 
Exclusion of participants with dementia—because we 
required patients to give fully informed consent (in line 
with the ethics committee guidance)—means our study 
results might not be applicable to those with non-bullous 
cutaneous pemphigoid (pre-pemphigoid). Placebo effect 
or regression to the mean is an unlikely explanation for 
the observed responses for doxycycline, given the 
progressive nature of bullous pemphigoid. Although no 
consideration of reverse multiplicity was made at the 
Raw dataset Imputed dataset
Prednisolone (n/N, %) 41/113 (36%) 40·0%*
Doxycycline (n/N, %) 22/121 (18%) 22·5%*
Adjusted† difference in 
proportions (%, 95% CI)
19·0% (7·9–30·1); 
p=0·001
18·4% (6·0–30·8); 
p=0·004
Unadjusted difference in 
proportions (%, 95% CI)
18·1% (6·9–29·3); 
p=0·002
17·5% (4·8–30·1); 
p=0·007
*Estimates from unadjusted regression model on imputed dataset. †Estimates 
are from a regression model adjusted for baseline severity of bullous 
pemphigoid; however, Karnofsky score and age were omitted from the model 
due to model non-convergence with it present.
Table 3: Proportion of participants experiencing at least one grade 3–5 
adverse event by 52 weeks that was possibly, probably, or definitely 
related to study treatment using a modified intention-to-treat 
analysis for a model based on the raw dataset and imputed dataset
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time the sample size was determined, the analyses of the 
primary effectiveness endpoint showed that the upper 
confidence difference for the effectiveness of the 
doxycycline group, 26·1%, was well below 37%, the 
chosen margin of non-inferiority, and the benefits in 
terms of safety were significant.27 The similarity of the 
inclusion criterion of three or more significant blisters to 
the primary success criterion of three or fewer blisters 
meant it was possible that some participants in the mild 
disease group experienced little change in blister status, 
although a sensitivity analysis was robust when excluding 
such participants from the analysis. Some degree of 
attribution bias could have occurred by wrongly assigning 
some unrelated serious adverse events as related ones, 
on the basis of knowledge of the side-effects of the study 
drugs. To reduce this, all unclear grade 3–5 events were 
reviewed by a senior independent dermatologist. It is 
unlikely that the safety outcomes at 52 weeks could be 
attributed to other drugs used after week 6. Similar 
proportions of patients received azathioprine (4% [ four 
of 113 patients] in the prednisolone group and 8% [ten of 
121 patients] in the doxycycline group) and no serious 
adverse drug reactions were attributed to azathioprine. 
Although bullous pemphigoid is characterised by a 
progressive course, the kinetics of its progression varies 
among patients, especially in patients with mild-to-
moderate disease. We failed to show any clear differences 
between mild, moderate, and severe disease in the short, 
medium, or long term, but it is possible that such 
differences could be shown in a much larger study or in 
an efficacy study done solely in patients with mild 
disease. Some of the participants in this study with 
milder or less progressive disease could have benefited 
from topical treatments. Dropouts for long-term 
outcomes were quite high, as anticipated in this frail 
elderly population, but were mostly due to withdrawal of 
consent and death rather than lack of effectiveness or 
adverse events (appendix p 2) and primary outcomes 
remained stable when adjusting for missing data for 
using multiple imputation.
The upper limit of the 90% CI around the difference of 
18·6% between the two treatment strategies (adjusted 
modified intention-to-treat analysis) is compatible with a 
difference as small as 26·1%, which falls well within the 
pre-determined 37% non-inferiority margin and is very 
close to the level of 25% in which a sample of 
dermatologists, when surveyed before the study (appendix 
p 1),17 said would be acceptable provided it was accompanied 
by a clinically important reduction in side-effects.
Definitions and outcomes for future trials in bullous 
pemphigoid proposed in 2015 (6 years after our study 
was designed) include 13 different outcome definitions 
according to the period of observation.28 Some might 
think that the absence of recording pruritus, which can 
herald the onset and recurrence of bullous pemphigoid, 
was a limitation of this study. However, it was always our 
intention to keep participant questionnaire burden to an 
absolute minimum in this pragmatic study in an elderly 
population, and quality-of-life measurements might have 
reflected symptoms such as itching, as well as other 
symptoms such as pain, burning, and soreness.
Because short-term control of blisters is less than 
optimal with doxycycline, future research might evaluate a 
strategy of starting all patients with a short course of super-
potent topical corticosteroids or prednisolone 0·5 mg/kg 
per day, followed by randomisation to maintenance 
treatment with either oral doxycycline or continuation with 
corticosteroids or other immunsuppressive maintenance 
treatments such as weekly oral methotrexate. Future 
studies should also consider including patients with 
bullous pemphigoid who have dementia, given the 
association of bullous pemphigoid with neurological 
diseases and the suggestion that tetracyclines might have 
neuroprotective properties.29,30 Although good progress has 
been made in identifying possible standardised outcomes 
such as the Bullous Pemphigoid Disease Area Index and 
other definitions for use in bullous pemphigoid trials,28 a 
minimum set of core outcome measures are still needed.
This study provides new evidence that doxycycline has 
a positive effect in controlling bullous pemphigoid 
blisters when used for initial treatment as part of a long-
term treatment strategy. The study confirms that oral 
prednisolone at a dose of 0·5 mg/kg per day is highly 
effective for mild-to-moderate disease, albeit at the 
expense of potentially serious, life-threatening, and fatal 
related adverse events compared with doxycycline. Both 
drugs are relatively cheap and available worldwide.
Where whole-body application of super-potent topical 
corticosteroids for months is not practical, a strategy of 
starting oral doxycycline plus localised application of 
potent topical corticosteroids to blisters15 might be 
considered in preference to the current standard practice 
of starting such patients on oral prednisolone. The 
estimates of the trade-off between reduced short-term 
effectiveness versus long-term safety gains according to 
disease severity obtained from this study now provide 
clear data to inform shared treatment decisions between 
health-care professionals and patients with bullous 
pemphigoid or their carers.
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